false
0001346830
0001346830
2024-01-17
2024-01-17
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
January 17, 2024
CARA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-36279 |
|
75-3175693 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
|
|
|
|
|
4 Stamford Plaza
107 Elm Street, 9th Floor
Stamford, Connecticut |
|
|
|
06902 |
(Address of principal executive offices) |
|
|
|
(Zip Code) |
|
|
|
|
|
Registrant's telephone number, including area code (203) 406-3700 |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title
of each class |
Trading
Symbol |
Name
of each exchange on which registered |
Common Stock, par value $0.001 per share |
CARA |
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨.
Item 2.05. |
Costs Associated with Exit or Disposal Activities. |
On January 17, 2024, in connection with a review of the company’s
strategic priorities, the Board of Directors of Cara Therapeutics, Inc. (the “Company”) approved a strategic reprioritization
to focus the Company’s resources on the Company’s late stage clinical program evaluating oral difelikefalin in pruritus associated
with notalgia paresthetica, and approved the termination of the Company’s Phase 3 clinical program evaluating oral difelikefalin
in pruritus associated with advanced chronic kidney disease, including the termination of the ongoing KICK 1 and KICK 2 clinical trials.
In connection with the termination of the oral chronic kidney disease program, the Board of Directors also approved a reduction in the
Company’s workforce, which the Company expects to substantially complete by January 31, 2024. The Company anticipates recognizing
between $2.5 million and $3 million in total charges in the first quarter of 2024 in connection with the reduction in force. These charges
will consist primarily of one-time cash charges for termination benefits.
Item 7.01. | Regulation
FD Disclosure. |
On January 22, 2024, the Company issued a press release (the “Press Release”) announcing its strategic reprioritization plan and the reduction in force. A copy of the press release is being furnished to the Securities and Exchange Commission as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference to this Item 7.01.
The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any of the Company’s filings with the Securities and Exchange Commission under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such a filing.
Item 8.01. | Other
Information. |
After giving effect to the strategic reprioritization and reduction
in force described herein, the Company now expects that its capital resources will be sufficient to fund its currently anticipated operating
plan into 2026.
On January 22, 2024, the Company also announced that Frédérique
Menzaghi, Ph.D., Chief Scientific Officer and SVP of Research & Development, will depart the Company, effective February 2,
2024.
Forward-Looking Statements
Statements contained in this report regarding matters that are not
historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.
Examples of these forward-looking statements include statements concerning the Company’s strategic plans to focus its resources
on the development of oral difelikefalin for the treatment of pruritus associated with notalgia paresthetica and to discontinue the development
of oral difelikefalin in advanced chronic kidney disease, the expected costs of the reduction in force and the timing of recognition of
such charges, and the Company’s cash runway. Because such statements are subject to risks and uncertainties, actual results may
differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include the risks
inherent in the clinical and regulatory development of pharmaceutical products, and the risks described more fully in Cara Therapeutics’
filings with the Securities and Exchange Commission, including the “Risk Factors” section of the Company’s Annual Report
on Form 10-K for the year ending December 31, 2022 and its other documents subsequently filed with or furnished to the Securities
and Exchange Commission, including its Form 10-Q for the quarter ended September 30, 2023. All forward-looking statements contained
in this report speak only as of the date on which they were made. Cara Therapeutics undertakes no obligation to update such statements
to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Item 9.01. |
Financial Statements and Exhibits. |
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CARA THERAPEUTICS, INC. |
|
|
|
By: |
/s/ RYAN MAYNARD |
|
|
Ryan Maynard |
|
|
Chief Financial Officer |
|
|
(Principal Financial and Accounting Officer) |
|
Date: January 22, 2024
Exhibit 99.1
Cara
Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 2026
– Focus on Phase 2/3
program in notalgia paresthetica (NP), a neuropathic disorder with significant unmet need –
– Phase 3 program in advanced
chronic kidney disease (CKD) to be discontinued –
– Planned workforce reduction
of up to 50% –
– Cara ended 2023 with approximately
$101 million in cash; runway extended into 2026 –
– Company to host conference
call and webcast today at 8:30 a.m. EST –
STAMFORD, Conn., January 22, 2024
– Cara Therapeutics, Inc. (Nasdaq: CARA) today announced it will focus its resources on the oral difelikefalin Phase 2/3 clinical
program in notalgia paresthetica (NP) and significantly reduce its operating expenses. These measures will extend the Company’s
cash runway into 2026, enabling the expected completion of the NP clinical program.
“We are sharpening our clinical
focus on the rapidly progressing Phase 2/3 study in NP, which we believe is the therapeutic indication with the greatest commercial potential
for oral difelikefalin,” said Christopher Posner, President and Chief Executive Officer of Cara Therapeutics. “Following careful
consideration, we have decided to discontinue our work in advanced chronic kidney disease (CKD). I would like to thank the patients and
investigators who have participated in our advanced CKD clinical program, as well as our employees for their commitment to transforming
the lives of CKD patients suffering from pruritus.”
Mr. Posner continued, “Unfortunately,
as a result of the difficult decision to restructure the Company, many of our talented team members will depart the organization. I am
deeply grateful for their dedicated service and support of our mission. We expect the changes we are making to extend our cash runway
into 2026, allowing us to reach all expected key value-inflection milestones in the NP clinical program.”
Focus on Late-Stage Notalgia Paresthetica Clinical Program
Enrollment in the Phase 2/3 clinical
program evaluating oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with NP, known as KOURAGE, is progressing
ahead of the Company’s projections. A data readout from the dose-finding portion of the program is expected in the third quarter
of 2024. Final topline results from the first pivotal study are expected by the end of 2025 with the second pivotal study results in early
2026.
NP is a common but under-recognized neuropathic
disorder characterized by chronic pruritus affecting the upper back. NP is challenging to manage, as there are currently no FDA-approved
therapies to treat the disorder. Oral difelikefalin is the only therapy in development for NP. NP represents a sizable, underserved patient
population with an estimated addressable market of 650,000 patients in the U.S. who are under the care of a healthcare provider, not accounting
for those who are undiagnosed.
Leadership Update
Frédérique Menzaghi, Ph.D.,
Chief Scientific Officer and SVP of Research & Development, will depart the Company, effective February 2, 2024.
“On behalf of the entire Cara team,
I would like to express our sincere gratitude to Fred for all her contributions and dedication to the organization over the past 20 years.
As one of Cara’s founders, her scientific leadership helped shape the trajectory of the company from start-up to a publicly traded
company,” said Mr. Posner.
Conference Call & Webcast
Cara will host a conference call and
webcast today at 8:30 a.m. EST to discuss the corporate update.
To
participate in the conference call, please register here. Registrants will receive the dial-in numbers and a unique PIN.
A live
audio webcast and archived replay of the call will be available under “Events & Presentations” in the Investors section
of the Company’s website at www.CaraTherapeutics.com.
About the KOURAGE Phase 2/3 Clinical Program in Notalgia
Paresthetica
KOURAGE is a Phase 2/3 clinical program
evaluating oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica (NP). The program
is comprised of two studies – KOURAGE 1 and KOURAGE 2 – which are double-blind, placebo-controlled, 8-week studies with patients
allowed to roll-over into open-label 52-week extensions.
KOURAGE 1 is composed of two parts. The
dose-finding portion of KOURAGE 1 (Part A) is expected to include 200 patients who will be randomized equally to four arms (0.25 mg BID,
1.0 mg BID, 2.0 mg BID, placebo BID). The Company expects a data readout from the dose-finding portion of KOURAGE 1 in the third quarter
of 2024. This readout will provide key information, specifically the dose and sample size to initiate the Phase 3 portions of the program
– Part B of KOURAGE 1 and the second pivotal study KOURAGE 2.
Part B and KOURAGE 2 will be double-blind,
placebo-controlled, 8-week studies with patients randomized 1:1 to either difelikefalin or matching placebo. The primary endpoint will
be the proportion of patients with a ≥4-point improvement at Week 8 from baseline in the worst itch numeric rating scale. The Company
expects final topline results from the first pivotal study by the end of 2025 with the second study by early 2026.
About Cara Therapeutics
Cara
Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering
from pruritus. The Company’s KORSUVA® (difelikefalin) injection is the first and only FDA-approved treatment for
moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral
formulation of difelikefalin, with an ongoing Phase 2/3 clinical program for patients with notalgia paresthetica, a neuropathic disorder
characterized by chronic pruritus of the upper back for which there are no FDA-approved therapies. For more information, visit www.CaraTherapeutics.com
and follow the company on X (Twitter), LinkedIn and Instagram.
Forward-looking Statements
Statements contained
in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995. Examples of these forward-looking statements include statements concerning
the Company’s strategic plans to focus its resources on the development of oral difelikefalin for the treatment of pruritus
associated with notalgia paresthetica and to discontinue the development of oral difelikefalin in advanced chronic kidney disease,
the timing of enrollment and data readouts from the Company’s planned and ongoing clinical trials, and the Company’s
cash runway. Because such statements are subject to risks and uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. These risks and uncertainties include the risks inherent in the launch of
new products, including that our commercial partners may not perform as expected, risks inherent in the clinical and regulatory
development of pharmaceutical products, and the risks described more fully in Cara Therapeutics’ filings with the Securities
and Exchange Commission, including the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the
year ending December 31, 2022 and its other documents subsequently filed with or furnished to the Securities and Exchange
Commission, including its Form 10-Q for the quarter ended September 30, 2023. All forward-looking statements contained in this press
release speak only as of the date on which they were made. Cara Therapeutics undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
MEDIA CONTACT:
Annie Spinetta
6 Degrees
973-768-2170
aspinetta@6degreespr.com
INVESTOR CONTACT:
Iris Francesconi, Ph.D.
Cara Therapeutics
203-406-3700
investor@caratherapeutics.com
v3.23.4
Cover
|
Jan. 17, 2024 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Jan. 17, 2024
|
Entity File Number |
001-36279
|
Entity Registrant Name |
CARA THERAPEUTICS, INC.
|
Entity Central Index Key |
0001346830
|
Entity Tax Identification Number |
75-3175693
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
4 Stamford Plaza
|
Entity Address, Address Line Two |
107 Elm Street
|
Entity Address, Address Line Three |
9th Floor
|
Entity Address, City or Town |
Stamford
|
Entity Address, State or Province |
CT
|
Entity Address, Postal Zip Code |
06902
|
City Area Code |
203
|
Local Phone Number |
406-3700
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common Stock, par value $0.001 per share
|
Trading Symbol |
CARA
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 3 such as an Office Park
+ References
+ Details
Name: |
dei_EntityAddressAddressLine3 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Cara Therapeutics (NASDAQ:CARA)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Cara Therapeutics (NASDAQ:CARA)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024